The content on this site is intended for healthcare professionals only
Dr Arend von Stackelberg speaks to ecancer about a talk he gave at the recent ALL Assembly 2021 meeting on 'treating late relapse of paediatric ALL'.
He discusses what the current options are for treating patients depending on MRD status and goes into the genetic subgroups which tend to have poorer outcomes.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Manageable safety profile with early efficacy of Tec-DR in NDMM
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis
